Astrazeneca (AZN) Receivables - Net (2015 - 2026)
Astrazeneca (AZN) posted quarterly Receivables - Net of $14.3 billion for Q2 2026, up 1.14% year-over-year from $14.2 billion in Q2 2025, and down 5.58% quarter-over-quarter from $15.2 billion in Q4 2025.
Astrazeneca (AZN) Receivables - Net (2015 - 2026) Analysis & Trends
Astrazeneca's Receivables - Net history runs 12 years deep, the most recent figure standing at $14.3 billion for Q2 2026.
- In Q2 2026, Receivables - Net rose 1.14% year-over-year to $14.3 billion; the TTM figure through Jun 2026 stood at $14.3 billion (up 1.14% YoY), while the FY2025 annual figure was $15.2 billion, up 17.0% from the prior year.
- Receivables - Net for Q2 2026 stood at $14.3 billion, down from $15.2 billion in the prior quarter.
- The five-year high for Receivables - Net was $15.2 billion in Q4 2025, with the low at $8.9 billion in Q2 2022.
- The 5-year median for Receivables - Net is $12.1 billion (2023), against an average of $12.3 billion.
- The sharpest annual moves came in 2022 and 2024: Receivables - Net surged 40.15% in 2022, then slipped 0.41% in 2024.
- Astrazeneca's Receivables - Net stood at $10.5 billion in 2022, then climbed by 15.26% to $12.1 billion in 2023, then climbed by 6.98% to $13.0 billion in 2024, then rose by 17.0% to $15.2 billion in 2025, then retreated by 5.58% to $14.3 billion in 2026.
- Business Quant data shows AZN's Receivables - Net at $14.3 billion in Q2 2026, $15.2 billion in Q4 2025, and $14.2 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.33 Bn |
| Jun 30, 2026 | 14.33 Bn |
| Dec 31, 2025 | 15.18 Bn |
| Dec 31, 2025 | 15.18 Bn |
| Jun 30, 2025 | 14.17 Bn |
| Jun 30, 2025 | 14.17 Bn |
| Dec 31, 2024 | 12.97 Bn |
| Dec 31, 2024 | 12.97 Bn |
| Jun 30, 2024 | 11.05 Bn |
| Jun 30, 2024 | 11.05 Bn |
| Dec 31, 2023 | 12.13 Bn |
| Dec 31, 2023 | 12.13 Bn |
| Jun 30, 2023 | 11.09 Bn |
| Jun 30, 2023 | 11.09 Bn |
| Dec 31, 2022 | 10.52 Bn |
| Dec 31, 2022 | 10.52 Bn |
| Jun 30, 2022 | 8.91 Bn |
| Jun 30, 2022 | 8.91 Bn |
| Dec 31, 2021 | 9.64 Bn |
| Dec 31, 2021 | 9.64 Bn |